Remedium Capital Partners, LLC
Portfolio value QoQ: +60.6% 13F does not disclose cash
Top 10 holdings weight100.00%
Top 25 holdings weight100.00%
Positions above 1%6
Effective number of positions4.1
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 1.81% Est. buys $7,618,699 · sells $6,636,163
New positions1
Increased2
Decreased0
Closed1
Portfolio value
$451.6M
Positions
6
As of
June 30, 2026 Data as of Q2 2026
Sector breakdown
Full portfolio 6 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| ORKA | $149,003,957 | 32.99% | 1,565,661 | $72,208,285 | |||
| SYRE | $129,988,924 | 28.78% | 1,464,169 | $56,536,632 | Up ×1 | ||
| APGE | $77,871,496 | 17.24% | 586,691 | $28,750,642 | Up ×1 | ||
| GLTO | $53,202,753 | 11.78% | 2,045,473 | $225,003 | |||
| JBIO | $35,057,605 | 7.76% | 1,577,750 | $12,890,217 | |||
| CBIO | $6,502,500 | 1.44% | 361,250 | Up ×1 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| CBIO | $6,502,500 | 361,250 | 1.44% |
Top movers (QoQ)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| CBIO | June 30, 2026 | 361,250 | $6,636,163 | -22.6% |